News related to Afinitor (Everolimus) and/or conditions it is approved for
Novartis drug Afinitor significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
Source: Endocrinology News From Medical News Today [2015.09.30]
Novartis has announced results of a Phase III pivotal study showing Afinitor® (everolimus) tablets reduced the risk of progression by 52% (hazard ratio [HR] = 0.
FDA OKs New Kids' Dose of Cancer Drug
Source: MedPage Today Product Alert [2012.08.30]
WASHINGTON -- The FDA has approved a pediatric dosage of the cancer drug everolimus (Afinitor Disperz) for the treatment of a rare brain tumor.
Everolimus First Drug to Show Effect in Lung NETs
Source: Medscape Hematology-Oncology Headlines [2015.10.01]
Already approved for use in pancreatic neuroendocrine tumors (NETs), the drug now shows efficacy in tumors originating in lung and gastrointestinal tract.
Medscape Medical News
Promising Tx in GI Neuroendocrine Tumors
Source: MedPage Today Gastroenterology [2015.09.27]
(MedPage Today) -- Significant boosts in PFS with radiopharmaceutical, everolimus